Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H22N4O3 |
| Molecular Weight | 354.403 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C2=C(C=C[C@@H](O2)C3CC3)C(CC4=C(N)N=C(N)N=C4)=C1
InChI
InChIKey=HWJPWWYTGBZDEG-CQSZACIVSA-N
InChI=1S/C19H22N4O3/c1-24-15-8-11(7-12-9-22-19(21)23-18(12)20)13-5-6-14(10-3-4-10)26-16(13)17(15)25-2/h5-6,8-10,14H,3-4,7H2,1-2H3,(H4,20,21,22,23)/t14-/m1/s1
| Molecular Formula | C19H22N4O3 |
| Molecular Weight | 354.403 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Aerie Pharmaceuticals, Inc. (Bridgewater, NJ), was developing a novel prostaglandin analog, AR-102, that had 150-fold greater selectivity and 30-fold greater potency at the FP receptor than latanoprost. In preclinical studies, the drug has shown greater IOP-lowering efficacy and alonger duration of action than latanoprost and betterocular tolerability than travoprost. AR-102 was in early-stage clinical development for glaucoma, which was discontinued later..
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. | 2003 Dec 1 |
|
| Infections associated with orthopedic implants. | 2006 Aug |
|
| Dihydrofolate reductase inhibitors as antibacterial agents. | 2006 Mar 30 |
|
| Gateways to clinical trials. | 2007 Dec |
|
| In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. | 2007 Dec |
|
| Effect of human plasma on the antimicrobial activity of iclaprim in vitro. | 2007 Dec |
|
| Iclaprim. | 2007 Sep |
|
| Current and novel antibiotics against resistant Gram-positive bacteria. | 2008 |
|
| [New antimicrobials against Gram-positive organisms]. | 2008 |
|
| Investigational antimicrobial drugs for bloodstream infections. | 2008 Aug |
|
| What's new and not so new on the antimicrobial horizon? | 2008 Dec |
|
| A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). | 2008 Feb |
|
| Pharmacologic options for CNS infections caused by resistant Gram-positive organisms. | 2008 Feb |
|
| Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. | 2008 Feb |
|
| Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. | 2008 Jan |
|
| Gateways to clinical trials. | 2008 Jun |
|
| The determinants of the antibiotic resistance process. | 2009 |
|
| Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. | 2009 Apr |
|
| Inhibitory properties and X-ray crystallographic study of the binding of AR-101, AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase from Staphylococcus aureus. | 2009 Aug |
|
| Activity of iclaprim against clinical isolates of Streptococcus pyogenes and Streptococcus agalactiae. | 2009 Feb |
|
| Antimicrobial development in the era of emerging resistance. | 2009 Jul |
|
| [New antibiotics: small or big advances?]. | 2009 Oct |
|
| New treatments for methicillin-resistant Staphylococcus aureus. | 2009 Oct |
|
| Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria. | 2009 Sep |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:41:12 GMT 2025
by
admin
on
Mon Mar 31 23:41:12 GMT 2025
|
| Record UNII |
7P9VLC9Y9D
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
44141864
Created by
admin on Mon Mar 31 23:41:12 GMT 2025 , Edited by admin on Mon Mar 31 23:41:12 GMT 2025
|
PRIMARY | |||
|
1208116-66-8
Created by
admin on Mon Mar 31 23:41:12 GMT 2025 , Edited by admin on Mon Mar 31 23:41:12 GMT 2025
|
PRIMARY | |||
|
7P9VLC9Y9D
Created by
admin on Mon Mar 31 23:41:12 GMT 2025 , Edited by admin on Mon Mar 31 23:41:12 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> ENANTIOMER |
|
||
|
|
RACEMATE -> ENANTIOMER |
|
